Results 181 to 190 of about 76,164 (271)

A High Throughput Microfluidic Approach for the Continuous Manufacture of Ibuprofen Nanocrystals

open access: yesAdvanced Materials Technologies, Volume 11, Issue 5, 6 March 2026.
A robust, continuous manufacturing platform using a high‐throughput microfluidic reactor addresses key scalability challenges in pharmaceutical production. This process efficiently generates crystalline ibuprofen nanoparticles with superior control over size and distribution.
Shorooq Abukhamees   +5 more
wiley   +1 more source

Emerging perspectives on leveraging physiologically based biopharmaceutics modeling (PBBM) for BCS class III biowaivers: A webinar summary. [PDF]

open access: yesJ Pharm Sci
Fang L   +8 more
europepmc   +1 more source

All‐PEG‐Like Block Copolymers Self‐Assemble into Stealth Nanocarriers for Drug Delivery

open access: yesAdvanced Science, Volume 13, Issue 17, 23 March 2026.
Self‐assembling nanoparticles composed entirely of POEGMA are engineered by exploiting side‐chain–dependent amphiphilicity and tunable thermoresponsive behavior. These single‐material nanocarriers encapsulate diverse hydrophobic drugs with high efficiency, retain therapeutic activity, improve in vivo efficacy, and evade anti‐PEG antibodies.
Parul Sirohi   +15 more
wiley   +1 more source

3D printing of acetaminophen suppository and its quality and pharmacokinetic evaluation. [PDF]

open access: yes3D Print Med
Chen M   +8 more
europepmc   +1 more source

Attenuated Bacteria‐Based Tumor Therapy: Clinical Application Risks, Marketing Approval Restrictions, and Coping Strategies

open access: yesAdvanced Science, Volume 13, Issue 16, 18 March 2026.
This review comprehensively overviews attenuated bacteria‐based tumor therapy, highlighting key methodologies and recent progress. It examines strategies for enhancing safety, stabilizing efficacy, optimizing manufacturing, and navigating regulatory pathways.
Yucheng Liu   +8 more
wiley   +1 more source

Pharmacokinetics, pharmacodynamics and safety of vutiglabridin after multiple oral administrations in healthy female and obese subjects

open access: yesBritish Journal of Clinical Pharmacology, Volume 92, Issue 3, Page 860-868, March 2026.
Aims Vutiglabridin (HSG4112) is a novel drug under clinical development for antiobesity treatment. This study aimed to evaluate the pharmacokinetics (PKs) and safety of vutiglabridin after multiple oral administrations in healthy Korean female and obese subjects and explore short‐term pharmacodynamic (PD) responses.
Sooyoun Lee   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy